Search Results - "Dubey, Sarita"

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study by Iveson, Timothy, Dr, Donehower, Ross C, MD, Davidenko, Irina, MD, Tjulandin, Sergey, Prof, Deptala, Andrzej, MD, Harrison, Mark, MD, Nirni, Somanath, MD, Lakshmaiah, Kuntegowdanahalli, MD, Thomas, Anne, Prof, Jiang, Yizhou, PhD, Zhu, Min, PhD, Tang, Rui, PhD, Anderson, Abraham, PhD, Dubey, Sarita, MD, Oliner, Kelly S, PhD, Loh, Elwyn, MD

“…Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,…”
Get full text

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307 by Dubey, Sarita, Jänne, Pasi A, Krug, Lee, Pang, Herbert, Wang, Xiaofei, Heinze, Robin, Watt, Colleen, Crawford, Jeff, Kratzke, Robert, Vokes, Everett, Kindler, Hedy Lee

“…Malignant mesotheliomas (MMs) express vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and cKIT. Sorafenib is a…”
Get more information

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology by Petrelli, Nicholas J, Winer, Eric P, Brahmer, Julie, Dubey, Sarita, Smith, Sonali, Thomas, Charles, Vahdat, Linda T, Obel, Jennifer, Vogelzang, Nicholas, Markman, Maurie, Sweetenham, John W, Pfister, David, Kris, Mark G, Schuchter, Lynn M, Sawaya, Raymond, Raghavan, Derek, Ganz, Patricia A, Kramer, Barnett

“…A MESSAGE FROM ASCO'S PRESIDENT As this report demonstrates—and as history shows—investment in clinical cancer research pays off. Since 1990, cancer mortality…”
Get full text

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer by Glisson, Bonnie, MD, Besse, Benjamin, MD, PhD, Dols, Manuel Cobo, MD, Dubey, Sarita, MD, Schupp, Marco, MD, Jain, Rajul, MD, Jiang, Yizhou, PhD, Menon, Hari, MD, Nackaerts, Kristiaan, MD, PhD, Orlov, Sergey, MD, PhD, Paz-Ares, Luis, MD, PhD, Ramlau, Rodryg, MD, PhD, Tang, Rui, PhD, Zhang, Yilong, PhD, Zhu, Min, PhD

“…ABSTRACT Introduction/Background: This randomized, double-blind, placebo-controlled phase 1b/2 study assessed the efficacy/safety of rilotumumab or ganitumab…”
Get full text

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies by CHIEN, Amy J, IIII, Julie A, SMALL, Eric J, JAHAN, Thierry M, HYLTON, Nola M, YEH, Benjamin M, YONG HUANG, KOCH, Kevin M, MOASSER, Mark M, KO, Andrew H, KORN, Wolfgang M, FONG, Lawrence, CHEN, Lee-May, KASHANI-SABET, Mohammed, RYAN, Charles J, ROSENBERG, Jonathan E, DUBEY, Sarita

“…Purpose: Systemic chemotherapy fails to access much of the tumor burden in patients with advanced cancer, significantly limiting its efficacy. In preclinical…”
Get full text

Latest information for the thoracic surgeon from the Annual Meeting of the American Society of Clinical Oncology by Dubey, Sarita, MD, Scagliotti, Giorgio, MD, PhD

Get full text

ACR Appropriateness Criteria® on Induction and Adjuvant Therapy for Stage N2 Non–Small-Cell Lung Cancer: Expert Panel on Radiation Oncology–Lung by Gopal, Ramesh S., M.D., Ph.D, Dubey, Sarita, M.D, Rosenzweig, Kenneth E., M.D, Chang, Joe Yujiao, M.D., Ph.D, Decker, Roy, M.D, Gewanter, Richard M., M.D, Kong, Feng-Ming, M.D., Ph.D., M.P.H, Lally, Brian E., M.D, Langer, Corey J., M.D, Lee, Hoon Ku, M.D, Movsas, Benjamin, M.D

“…“The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through…”
Get full text

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial by Pal, Sumanta Kumar, Uzzo, Robert, Karam, Jose Antonio, Master, Viraj A, Donskov, Frede, Suarez, Cristina, Albiges, Laurence, Rini, Brian, Tomita, Yoshihiko, Kann, Ariel Galapo, Procopio, Giuseppe, Massari, Francesco, Zibelman, Matthew, Antonyan, Igor, Huseni, Mahrukh, Basu, Debasmita, Ci, Bo, Leung, William, Khan, Omara, Dubey, Sarita, Bex, Axel

“…The standard of care for locoregional renal cell carcinoma is surgery, but many patients experience recurrence. The objective of the current study was to…”
Get full text

13. Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC) with Spinal Metastases by Guillaume, Tenner J., MD, Dubey, Sarita, MD, Hu, Serena S., MD, Berven, Sigurd H., MD, Tay, Bobby K-B, MD, Deviren, Vedat, MD, Burch, Shane, MD

Get full text

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study by Pal, Sumanta K, McGregor, Bradley, Suárez, Cristina, Tsao, Che-Kai, Kelly, William, Vaishampayan, Ulka, Pagliaro, Lance, Maughan, Benjamin L, Loriot, Yohann, Castellano, Daniel, Srinivas, Sandy, McKay, Rana R, Dreicer, Robert, Hutson, Thomas, Dubey, Sarita, Werneke, Scott, Panneerselvam, Ashok, Curran, Dominic, Scheffold, Christian, Choueiri, Toni K, Agarwal, Neeraj

“…COSMIC-021 is evaluating cabozantinib plus atezolizumab in patients with solid tumors. We report results from patients with advanced clear cell (cc) and…”
Get full text

ACR Appropriateness Criteria® Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent by Gewanter, Richard M., MD, Rosenzweig, Kenneth E., MD, Chang, Joe Yujiao, MD, PhD, Decker, Roy, MD, Dubey, Sarita, MD, Kong, Feng-Ming, MD, PhD, MPH, Lally, Brian E., MD, Langer, Corey J., MD, Lee, Hoon Ku, MD, Movsas, Benjamin, MD

“…The optimal strategy for the non-surgical definitive treatment of patients with good performance status non-small cell lung cancer (mostly with locally…”
Get full text

Phase I trial of perillyl alcohol administered four times daily continuously by MORGAN-MEADOWS, Sherry, DUBEY, Sarita, ELLINGEN, Shawna, BLACK, Sandra, POMPLUN, Marcia, WILDING, George, BAILEY, Howard, GOULD, Michael, TUTSCH, Kendra, MARNOCHA, Rebecca, ARZOOMANIN, Rhoda, ALBERTI, Dona, BINGER, Kimberly, FEIERABEND, Chris, VOLKMAN, Jennifer

“…Previous experience with perillyl alcohol (POH) was with a formulation of 500-mg capsules each containing 250 mg POH and soybean oil. This formulation resulted…”
Get full text

Smoking cessation: an integral part of lung cancer treatment by Cataldo, Janine K, Dubey, Sarita, Prochaska, Jodi J

“…Lung cancer is the leading cause of cancer death in the US. About 50% of lung cancer patients are current smokers at the time of diagnosis and up to 83%…”
Get more information

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma by Motzer, Robert J, Powles, Thomas, Atkins, Michael B, Escudier, Bernard, McDermott, David F, Alekseev, Boris Y, Lee, Jae-Lyun, Suarez, Cristina, Stroyakovskiy, Daniil, De Giorgi, Ugo, Donskov, Frede, Mellado, Begoña, Banchereau, Romain, Hamidi, Habib, Khan, Omara, Craine, Veronica, Huseni, Mahrukh, Flinn, Nick, Dubey, Sarita, Rini, Brian I

“…Interim analyses of the IMmotion151 trial (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced…”
Get more information

Update in Lung Cancer 2008 by DUBEY, Sarita, POWELL, Charles A

Get full text

Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) by Rini, Brian I., Atkins, Michael B., Escudier, Bernard, Powles, Thomas, McDermott, David F., Alekseev, Boris Y., Lee, Jae-Lyun, Stroyakovskiy, Daniil, Rodriguez, Cristina Suarez, De Giorgi, Ugo, Donskov, Frede, Mellado, Begoña, Banchereau, Romain, Hamidi, Habib, Khan, Omara, Craine, Veronica, Huseni, Mahrukh, Flinn, Nick, Dubey, Sarita, Motzer, Robert

“…Abstract Background: In IMmotion151 (NCT02420821), atezo (anti-PD-L1) + bev (anti-VEGF) improved PFS vs sun as 1L treatment in patients (pts) with mRCC (Rini,…”
Get full text

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone by RYAN, Charles J, ROSENTHAL, Mark, MIN ZHU, RUI TANG, OLINER, KellyS, YIZHOUJIANG, LOH, Elwyn, DUBEY, Sarita, GERRITSEN, Winald R, NG, Siobhan, ALUMKAL, Joshi, PICUS, Joel, GRAVIS, Gwenaëlle, FIZAZI, Karim, FORGET, Frédéric, MACHIELS, Jean-Pascal, SRINIVAS, Sandy

“…To evaluate the efficacy, safety, biomarkers, and pharmacokinetics of rilotumumab, a fully human, monoclonal antibody against hepatocyte growth factor…”
Get full text

Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial by Abou-Alfa, Ghassan K., Meyer, Tim, Cheng, Ann-Lii, Cicin, Irfan, Bolondi, Luigi, Klümpen, Heinz Josef, Chan, Stephen Lam, Dadduzio, Vincenzo, Milwee, Steven, Dubey, Sarita, Kelley, Robin Kate, El-Khoueiry, Anthony B.

“…Abstract only 4088 Background: Class-specific AEs occurring with tyrosine kinase inhibitors have been associated with improved efficacy outcomes in several…”
Get full text

Update in Lung Cancer 2007 by DUBEY, Sarita, POWELL, Charles A

Get full text

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study by Traynor, Anne M, Dubey, Sarita, Eickhoff, Jens C, Kolesar, Jill M, Schell, Kathleen, Huie, Michael S, Groteluschen, David L, Marcotte, Sarah M, Hallahan, Courtney M, Weeks, Hilary R, Wilding, George, Espinoza-Delgado, Igor, Schiller, Joan H

“…Vorinostat is a small molecule inhibitor of histone deacetylase, and has shown preclinical activity in non-small cell lung cancer (NSCLC). Patients with…”
Get more information